CLEU19025 / A041701 / Chemo + Uproleselan for AML / Jane LiesveldResearch Question:
How well does daunorubicin and cytarabine with or without uproleselan works in treating
older adult patients with acute myeloid leukemia receiving intensive induction chemotherapy?
Basic Study Information
Purpose:Location: University of Rochester Medical Center
This phase II/III trial studies how well daunorubicin and cytarabine with or without
uproleselan works in treating older adult patients with acute myeloid leukemia receiving
intensive induction chemotherapy. Drugs used in chemotherapy, such as daunorubicin
and cytarabine, work in different ways to stop the growth of cancer cells, either
by killing the cells, by stopping them from dividing, or by stopping them from spreading.
Uproleselan may prevent cancer from returning or getting worse. Giving daunorubicin
and cytarabine with uproleselan may work better in treating patients with acute myeloid
leukemia compared to daunorubicin and cytarabine alone.
Study Reference #: CLEU19025
Lead Researcher (Principal Investigator)
Jane Liesveld, MD
Study Contact InformationStudy Coordinator: Tina Bowdish
Phone: +1 585-275-9475
Additional Study Details
Trial Not Found
The study you are looking for is not active at this time.
Return to Search